Illingworth Group is a leading european clinical Group organisation (CRO) providing a wide range of clinical development and medical photography services to the healthcare, biotechnology, medical device and international pharmaceutical industries.
Illingworth Group was founded in 1998 as Clinical Development and Support Services Ltd (CDSS). By 2010, the company had significantly expanded both its clinical development services and its Group nursing provision. Taking a strategic decision to divide the business and allow both units to pursue their core activities with their own distinct identities, John Illingworth and his team embarked upon a major project to create and launch two new brands into the marketplace in 2011.
Intract Pharma Limited is an oral drug delivery licensing and product development company offering a range of proprietary formulation technologies to deliver novel and optimised therapeutics targeted to patient needs. The company is a spin-out of University College London, and is centred around over 15 years of research and innovation from the laboratory of Professor Abdul Basit. Intract's range of formulation technologies includes Phloral™ for colon targeted delivery, and ProRelease™, a versatile microparticulate delivery system.
J A Kemp
We are one of the largest UK and European Patent and Trade Mark Attorney firms, with offices in London, Oxford, Cambridge and Munich.
The breadth and depth of our technical knowledge relevant to patents is outstanding, with over 50 science and technology graduates in the firm including over 30 PhDs. No area of science or technology is outside our scope.
Karma Oncology is an oncology specialized clinical research organisation. With a team of very experienced oncology project managers, CRAs and CTAs we offer all clinical trial services from preparation of clinical development plans including protocol design, project/study management, monitoring, data review, preparation of the clinical study report and manuscript. Services are customised to individual sponsors and as such we will perform any single aspect of a trial as efficiently and with the same enthusiasm and dedication as we will for the complete trial.
Lucy J Robertshaw specialize in the Anglo Nordic Life Sciences sectors. Our expertise includes match making for export opportunities and talent spotting for investment. We are immersed in the market and highly visible at important industry events. We have many years experience within the Pharmaceutical sector bringing a wealth of knowledge and expertise to our clients who are looking to develop their business. We have personal and professional relationships with key players and an ear to the ground in Scandinavia and the UK. We understand the challenges within the life science sector and bring a new outlook to business development. We are offering clients support, from an idea they may have, to understanding how to create a business model and right through to ensure they are marketed correctly with the right strategy.
Masters Speciality Pharma
Founded over 30 years ago, Masters Speciality Pharma is an international pharmaceutical company specialising in the distribution of unlicensed medicinal products to Physicians, Hospitals, Clinics, Government institutions and individual patients, providing access to essential life-saving treatments worldwide.
Masters is fully compliant with regulatory requirements in all jurisdictions enabling us to deliver tailored medical solutions to over 90 countries worldwide, and is trusted as a reliable source of pharmaceutical product
Medherant is developing a pipeline of products for pain and neurology indications, based on our next-generation TEPI-Patch® transdermal drug technology. Our first product – Ibuprofen TEPI Patch – entered the clinic in 2018.
Key advantages of the TEPI Patch® technology over current technologies are the high payload and very efficient release of drug. This enables lower potency drugs to be formulated as a patch and provides the opportunity to increase the dose of drugs already administered via a patch whilst also minimising the residual drug after use.
The TEPI Patch® also provides a better experience for the user as it does not leave a residue around the patch – referred to as ‘cold flow’ – and has excellent adhesion whilst still being easy and painless to remove. No organic solvents are involved in this drug-in-adhesive system.
As well as developing our own products, Medherant offers pharma companies rapid feasibility studies using our proprietary high throughput permeation study system to develop transdermal formulations of their drugs of interest.
MediWales is the life science network and representative body for Wales. An independent, not-for-profit organisation that is owned by its members, MediWales provides advice, support, business opportunities and promotes collaborations for the life science and health technology community in Wales.
MediWales delivers an extensive events programme, including the UK HealthTech conference and the MediWales Innovation Awards and produces a number of publications including UK Lifescience Industry magazine, the Annual Directory and Review, and case study magazine LifeStories. MediWales promotes and supports its members in Wales, across the UK and internationally.
metaLinear offers a fast track to highly validated drug targets and lead compounds, some of which will be available for licensing. Our focus is on antibiotics/antibiotic resistance. Our proven technology manipulates proteins inside living cells, reaching the >90% of biology inaccessible to siRNA or CAS/Crispr.
metaLinear was established in November 2016 and began operating from the Biohub at Alderley Park in Cheshire from March 2017. Operated by life science incubation specialist, The BioCity Group, Biohub supports the creation and growth of successful life science companies including Redx, Blueberry Therapeutics and the Anti-Microbial Research Centre.